HomeCorporateZoetis Secures USDA Licence for Poulvac Procerta HVT-ND-ILT, a 3-Way Vector Vaccine...

Zoetis Secures USDA Licence for Poulvac Procerta HVT-ND-ILT, a 3-Way Vector Vaccine for Chickens

Zoetis has received a United States Department of Agriculture (USDA) licence for Poulvac® Procerta® HVT-ND-ILT, a recombinant vector vaccine designed to protect chickens against three important poultry diseases: Marek’s disease (MD), Newcastle disease (ND) and infectious laryngotracheitis (ILT).

Announced on 19 November 2026, the licence adds a new option to the company’s poultry vaccine portfolio and reflects continued investment in combination and vector-based approaches to flock-health management.

Three disease targets in one vaccine platform

Poulvac Procerta HVT-ND-ILT uses a herpesvirus of turkeys (HVT) vector platform. HVT is widely used in poultry vaccination, particularly for Marek’s disease, and recombinant HVT technologies allow selected protective antigens from other pathogens to be expressed through the vector. The new product is designed to provide protection against:

  1. Marek’s disease: A highly consequential viral disease associated with lymphoid tumours, immunosuppression and production losses.

  2. Newcastle disease: A highly contagious viral infection that can cause respiratory, digestive and neurological signs, with severity varying by virus strain and bird susceptibility.

  3. Infectious laryngotracheitis: A respiratory disease that can cause severe respiratory distress, reduced egg production and mortality in affected flocks.

Combining three disease targets within one vector-based vaccine is intended to simplify the hatchery vaccination strategy and provide an additional tool for poultry veterinarians and producers.

Hatchery administration and programme flexibility

The product is labelled for administration to healthy one-day-old chickens or in ovo vaccination in 18- to 19-day-old embryonated chicken eggs. These routes allow it to be incorporated into hatchery-based vaccination programmes, where large numbers of birds can be vaccinated in a controlled environment.

The company describes the vaccine as providing early and long-lasting protection. Actual protection and programme performance will depend on the product label, flock conditions, maternal antibody status, vaccination handling and the wider vaccination programme.

Zoetis also indicates that the vaccine is designed to fit into rotational hatchery programmes alongside modified-live ILT vaccines. This is an important practical point: a vector vaccine should not be treated as a universal replacement for every existing ILT vaccination approach. Veterinary teams need to consider the timing and compatibility of the full programme.

Why the development matters to commercial poultry production

Respiratory disease complexes can create substantial economic costs. Newcastle disease and ILT can affect flock performance, mortality, feed efficiency and egg production, while Marek’s disease can cause losses through tumour development and immunosuppression. A multi-target vaccine can offer several potential operational advantages:

  • Fewer separate vaccination interventions at the hatchery

  • More streamlined vaccine handling and administration

  • An additional option for integrated disease-prevention programmes

  • Potentially more consistent early-life vaccination coverage

  • Greater flexibility for veterinary teams managing complex vaccination schedules

However, combination products do not eliminate the need for biosecurity, surveillance or appropriate disease-specific vaccination decisions. They also do not guarantee protection against every circulating strain or field challenge.

Implications for the poultry vaccine market

The licence is relevant to a global poultry industry increasingly focused on hatchery automation, early-life disease prevention and reducing the operational complexity of vaccination programmes.

For vaccine manufacturers, recombinant vector platforms offer opportunities to combine antigen targets and develop products that fit modern integrated production systems. For poultry integrators, the value proposition will depend on demonstrated protection, ease of administration, cost per chick and the ability to integrate the product into existing hatchery workflows.

The USDA licence is a regulatory milestone in the United States. It should not be interpreted as automatic authorisation in other countries, including India. Local registrations, product availability and label conditions will need to be confirmed separately.

Animal Health India Editorial Team
Animal Health India Editorial Teamhttps://animalhealthindia.com
Animal Health India (AHI) is an independent news and intelligence platform covering the global animal health, veterinary, livestock, poultry, companion animal and pet food sectors. Our editorial team comprises veterinary journalists, animal health professionals, regulatory affairs specialists and industry analysts with over 30 years of combined experience covering India, Asia, Europe and North America. AHI publishes news, regulatory updates, market intelligence and company news drawn from primary sources including DAHD, EMA, USDA, AVMA and leading veterinary publications worldwide.
RELATED ARTICLES